0001104659-19-004075.txt : 20190129 0001104659-19-004075.hdr.sgml : 20190129 20190129163126 ACCESSION NUMBER: 0001104659-19-004075 CONFORMED SUBMISSION TYPE: 6-K/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190129 FILED AS OF DATE: 20190129 DATE AS OF CHANGE: 20190129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProQR Therapeutics N.V. CENTRAL INDEX KEY: 0001612940 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36622 FILM NUMBER: 19549044 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333CR BUSINESS PHONE: 31(0)88 166 7000 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333CR FORMER COMPANY: FORMER CONFORMED NAME: ProQR Therapeutics B.V. DATE OF NAME CHANGE: 20140708 6-K/A 1 a19-3670_16ka.htm 6-K/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K/A

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

January 29, 2019

 

PROQR THERAPEUTICS N.V.

 

Zernikedreef 9

2333 CR Leiden

The Netherlands

Tel: +31 88 166 7000

(Address, Including ZIP Code, and Telephone Number,
Including Area Code, of Registrant’s Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x  Form 40-F  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

 

 

 


 

EXPLANATORY NOTE

 

The original report on Form 6-K dated January 29, 2019 incorrectly stated the file number of the registration statement on Form F-3 into which Exhibit 99.1 (Press Release of ProQR Therapeutics N.V. dated January 29, 2019, titled “ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day”) should be incorporated by reference. This report on Form 6-K/A is furnished solely to incorporate by reference such Exhibit 99.1 into the registration statement on Form F-3 (File No. 333-228251).

 

Other than as expressly set forth above, this Form 6-K/A does not, and does not purport to, amend, update or restate the information in any other item of the original Form 6-K, or reflect any events that have occurred after the Form 6-K was originally filed.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

PROQR THERAPEUTICS N.V.

 

 

 

Date: January 29, 2019

By:

/s/ Smital Shah

 

 

Smital Shah

 

 

Chief Financial Officer

 

3